A Study to Determine the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • STATUS
    Recruiting
  • End date
    Nov 25, 2022
  • participants needed
    69
  • sponsor
    AbbVie
Updated on 6 August 2021
Investigator
AbbVie_Call Center
Primary Contact
Rabin Medical Center /ID# 215230 (6.6 mi away) Contact
+49 other location

Summary

The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Details
Condition Advanced Solid Tumors Cancer
Treatment Nab-paclitaxel, ABBV-181, ABBV-368, Tilsotolimod
Clinical Study IdentifierNCT04196283
SponsorAbbVie
Last Modified on6 August 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Participants should weigh at least 35 kg
Eastern Cooperative Oncology Group performance status of 0 or 1 and a life expectancy of >= 3 months
Participant have >= 1 lesion accessible for intratumoral injection
Histologically or cytologically confirmed R/M HNSCC (of the following 4 subsites: oral cavity, oropharynx, larynx, and hypopharynx) who previously progressed either during or after <= 3 prior treatment regimens administered in the recurrent or metastatic setting
Must have received 1 immunotherapy regimen which included a PD-(L)1 inhibitor
Must have received platinum-based therapy, or be considered ineligible for platinum-based therapy by the investigator

Exclusion Criteria

Uncontrolled metastases to the central nervous system (CNS)
Participants with brain metastases are eligible provided that evidence of clinical and radiographic stable disease for at least 4 weeks after definitive therapy is given and participants have not used prohibited levels of steroids for at least 4 weeks prior to first dose of the study
Received prior treatment with OX40 or toll-like receptor (TLR) agonists (excluding topical agents)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note